A Low Dose of Vitamin D Nearly Doubled Chemo Success in Breast Cancer Patients

A small but carefully designed randomized trial out of Brazil is drawing attention for a striking result: women with breast cancer who took a daily vitamin D supplement while undergoing pre-surgical chemotherapy saw complete tumor disappearance at nearly twice the rate of those who took a placebo. The study, published in Nutrition and Cancer in 2025, was conducted at the Botucatu School of Medicine at São Paulo State University (FMB-UNESP). The findings are preliminary, but the signal is strong enough to justify a much closer look.

Vitamin D supplementation and complete tumor disappearance rates

Among the 40 women who received 2,000 IU of vitamin D per day, 43% achieved what researchers call a pathologic complete response, meaning no detectable cancer remained after chemotherapy. In the 40 women who received a placebo, that figure was just 24%. That translates to a 79% improvement in the rate of complete cancer disappearance, a result that held up statistically despite the modest sample size.

What makes the dose noteworthy is how conservative it is. The standard therapeutic dose for correcting vitamin D deficiency runs around 50,000 IU per week. The dose used here, 2,000 IU daily, is not far above what current adult guidelines already recommend for bone health. Lead researcher Eduardo Carvalho-Pessoa noted that "even with a small sample of participants, it was possible to observe a significant difference in the response to chemotherapy," adding that the dosage "is far below the target dose for correcting vitamin D deficiency."

At the start of the trial, most participants had low vitamin D levels, below 20 ng/mL, well under the 40 to 70 ng/mL range that the Brazilian Society of Rheumatology considers optimal. Levels in the supplementation group rose steadily throughout treatment, and Carvalho-Pessoa observed that this sustained increase "reinforces a possible contribution to the patients' recovery."

Why this finding matters for breast cancer patients globally

Breast cancer is not a rare disease, and its treatment burden is enormous. In the United States alone, breast cancer accounts for 14% of all cancer treatment costs, roughly $29.8 billion in 2020. Globally, the picture is worsening: projections from GLOBOCAN data estimate that annual breast cancer cases will exceed 6 million by 2050, with the sharpest increases expected in Asia and Africa.

Neoadjuvant chemotherapy, the kind used in this study, is given before surgery to shrink tumors and make them easier to remove. Achieving a complete pathologic response at that stage is a meaningful clinical milestone: it is associated with better long-term outcomes. If a supplement as accessible and inexpensive as vitamin D can meaningfully raise that response rate, the implications extend well beyond Brazil.

Carvalho-Pessoa was direct about this dimension of the finding. Vitamin D, he pointed out, is "an accessible and inexpensive option compared to other drugs used to improve the response to chemotherapy, some of which are not even included in the list" of Brazil's national public health system. In settings where cutting-edge oncology drugs are scarce or unaffordable, a cheap supplement that nudges chemotherapy outcomes would matter enormously.

How the trial was designed and what it measured

The study enrolled 80 women over age 45 who had been diagnosed with breast cancer and were scheduled to begin neoadjuvant chemotherapy. Participants were randomly assigned to receive either 2,000 IU of vitamin D per day or an identical-looking placebo tablet for the six-month duration of their chemotherapy course. The primary outcome was pathologic complete response, assessed after the full treatment period.

The design is straightforward and the randomization controlled for the key confounders. The sample is, by the researchers' own admission, small. But the effect size was large enough to achieve statistical significance even at 80 participants, which is itself informative: small trials with large effects are often the first signal that something real is happening. Earlier work, including a meta-analysis of randomized controlled trials on vitamin D and breast cancer risk, found no conclusive evidence that supplementation reduces initial cancer risk. This study asks a different question: not whether vitamin D prevents breast cancer, but whether it changes how existing tumors respond to treatment.

Open questions about dose, mechanism, and patient selection

The trial raises more questions than it answers, which is typical of early-stage research. The most pressing involve mechanism: how, exactly, might vitamin D improve chemotherapy response? Vitamin D receptors are present in breast tumor cells, and the hormone-like molecule is known to influence cell proliferation, apoptosis, and immune function. A detailed review of vitamin D's genomic pathways and role in breast cancer metabolism notes that further research is needed to clarify tissue specificity, optimal dosages, and how vitamin D interacts with different molecular subtypes of breast cancer, including triple-negative, hormone-receptor-positive, and HER2-positive tumors.

The study population here was women over 45, most of whom started with deficient vitamin D levels. Whether similar benefits would appear in younger women, in patients with adequate baseline vitamin D, or across different breast cancer subtypes remains unknown. The dose question is also unresolved: if 2,000 IU per day produces this effect, do higher doses produce more, or does the benefit plateau or even reverse?

Excessive vitamin D is not without risk. Very high intake can cause vomiting, weakness, bone pain, and kidney stones. The conservative dose used in this trial was likely chosen with that in mind, and its apparent effectiveness at a sub-therapeutic level is one of the more intriguing aspects of the result.

Larger trials are already underway

The research community is not waiting. An ongoing Phase II clinical trial registered at ClinicalTrials.gov is specifically testing whether vitamin D supplementation during neoadjuvant chemotherapy can increase pathologic complete response rates in patients with vitamin D deficiency and operable triple-negative breast cancer, one of the most aggressive and hardest-to-treat subtypes. Results from that trial, conducted at a larger scale, will be critical for determining whether the FMB-UNESP findings replicate.

For now, the São Paulo study stands as a compelling early signal. A 79% improvement in complete tumor disappearance from a supplement that costs pennies a day and carries a well-understood safety profile at moderate doses is exactly the kind of finding that earns a larger investigation. The critical next step is confirmation in a bigger, more diverse patient population before clinicians can consider routine supplementation as part of a neoadjuvant chemotherapy protocol.

Evidence rating

INVESTIGATIONAL — 65/100

Caveats:

• Small trial of only 80 participants — results need confirmation in larger studies before conclusions can be drawn.
• A relative improvement of 79% reflects a shift from 24% to 43% absolute response rate — the absolute difference is 19 percentage points.
• The mechanism by which vitamin D enhances chemotherapy response is not yet established.
• Findings have not been independently replicated; larger trials are needed.

Small randomized controlled trial (n=80). Reports a statistically significant difference in pathological complete response rates between vitamin D and placebo groups, but the limited sample size means the result should be treated as preliminary. The proposed immune-modulatory mechanism is plausible but not yet established. Independent replication in larger, more diverse populations is needed before these findings can be considered robust.

References

1. Michelle Sako Omodei, Jackeline Chimicoviaki, Daniel Araujo Brito Buttros, et al. (2025). Vitamin D Supplementation Improves Pathological Complete Response in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Randomized Clinical Trial. Nutrition and Cancer. https://doi.org/10.1080/01635581.2025.2480854
2. Health and Economic Benefits of Breast Cancer Interventions – CDC. cdc.gov. https://www.cdc.gov/cancer/breast/cost/index.htm
3. Omar Freihat, David Sipos, Arpad Kovacs (2025). Global burden and projections of breast cancer incidence and mortality to 2050: a comprehensive analysis of GLOBOCAN data. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1622954
4. Francesca Sperati, Patrizia Vici, Marcello Maugeri-Saccà, et al. (2013). Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. PLoS ONE. https://doi.org/10.1371/journal.pone.0069269
5. Carmen J. Narvaez, Donald Matthews, Erika LaPorta, Katrina M. Simmons, Sarah Beaudin, JoEllen Welsh (2014). The impact of vitamin D in breast cancer: genomics, pathways, metabolism. Frontiers in Physiology. https://doi.org/10.3389/fphys.2014.00213
6. Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients – ClinicalTrials.gov. clinicaltrials.gov. https://clinicaltrials.gov/study/NCT04677816